With the emergence of nanotechnology the number of manufactured nanomaterials (MNM) in production and use is constantly increasing. Exposure of workers to MNM is of concern, because still much is unknown about health effects. MNM may have different properties, testing of each material is time consuming and costly. Experts have proposed various approaches to categorize MNM to facilitate risk assessment of human health effects based on shared properties of various materials. A systematic literature survey was undertaken to identify expert opinions on grouping of MNM published between the years 2000 and 2015. We summarized and synthesized the opinions according to a systematic review of text and opinion. We identified 22 articles that fulfilled our inclusion criteria reporting 17 proposals with three proposals for groups and 14 proposals for criteria for grouping. Five proposals suggested one or more of the following groups of concern: fibrous, biopersistent, high solubility with high toxicity, chemically active. Criteria proposed in multiple studies were: viable testing options, mode of action, physicochemical properties predicting toxicity. We conclude that a limited number of groups have been proposed to categorize MNM according to human health concern. Further research should be conducted to underpin the proposed groups with empirical evidence.
Introduction
Nanomaterials are especially developed for their useful technological properties and they are used in an ever increasing number of commercial products. In addition to useful properties the change to the nanoscale may also have effects that are harmful to health. The rapid increase in development and production of manufactured nanomaterials (MNM) and the potential harmful health effects different from those of their larger counterparts makes it urgent to find reliable risk assessment methods (Alshehri et al., 2016; Jain et al., 2018; Piccinno et al., 2012) . Occupational exposure of workers to MNM is of particular concern because they may be exposed for longer time periods and the exposure levels may be higher compared to consumers of nanomaterial containing products. With the large number of new materials to be produced in the future, there is a need to prioritize the most relevant for risk management. Proper material characterization has been pointed out as a key element in hazard identification and the subsequent risk assessment of MNM (Krug, 2014) . Many of the published articles in the literature have inadequately dealt with physicochemical characterization or have poor quality material characterization and therefore most of the scientific journals have set up a minimum list of material characterization to be performed (Hussain et al., 2015) .
In the approach used by the European Chemical Agency (ECHA) chemical substances that have similar properties may be placed in groups for the purpose of risk evaluation. ECHA uses the following definition of a group: "Substances that are structurally similar with physicochemical, (eco)toxicological, and/or environmental fate properties that are likely to be similar or follow a regular pattern" (ECHA, 2013) . Such similarities may be due to common functional groups, common precursors, or likely common breakdown products. Within a group of substances, each individual substance may not need to be tested. Instead, endpoint specific effects of an unknown substance may be derived from the endpoint-specific effects of the other substances within the group. This approach is known as 'Read-across' which is the application of the grouping concept to fill the knowledge gap for one substance in a group of MNM by using data from the same endpoint from another MNM. Oomen et al., among others, have defined grouping or categorization of MNM along similar lines (Oomen et al., 2014 (Oomen et al., , 2015 . They state that the term "group" or "category" represents a number of MNM, which share commonalities relevant for risk, i.e. one or more common properties in a physical, chemical, exposure, toxicological endpoints, toxicokinetics or fate. It is assumed that the knowledge of MNM similarities and their subsequent categorization into groups with similar biological endpoints will facilitate hazard identification and the risk evaluation processes. However, given the complexity of MNM and the limited knowledge on how they may affect human health, various grouping approaches have been proposed. As part of the WHO project to develop guidelines for protecting workers from potential risks of manufactured nanomaterials the following question was formulated: 'which specific MNM and groups of MNM are most relevant with respect to reducing risks to workers and which should this guideline now focus on, taking into account toxicological considerations and quantities produced and used.' To find answers to this question we wanted to identify the various approaches for grouping MNM.
Therefore, the aim of this review is to give an overview of the published opinions (in the timeframe [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] of experts that propose strategies for grouping and categorization of MNM and to identify similarities and differences in the criteria that they use for grouping. A distinction between this review and other published reviews is that our approach was to identify only reviews and opinions and to impartially present the views of the authors. Furthermore, we focused only on the grouping approaches relevant for hazard assessment of MNM in occupational settings.
Methods
We followed a systematic review approach with the inclusion criteria defined by an adapted PICO approach P for Participants, I for Intervention, C for Control and O for Outcomes (Morgan et al., 2016) . We adapted our specific PICO question following methods proposed for systematic reviews of text and opinion (https://joannabriggs.org/ assets/docs/sumari/ReviewersManual-2014.pdf). Our specific PICO question was as follows: For workers exposed to MNM, which criteria are proposed by experts to group MNM into categories with similar toxicological properties. To be included the scientist or group of scientists had to propose explicit criteria for grouping based on a specific theory or toxicological arguments including those taken from published studies. We did not however, ourselves include empirical studies on toxicological properties of specific MNM such as animal (in vivo) or in vitro studies. Information on nanomaterials metrics was included whenever addressed by the experts, but was not a primarily aim in this review. In addition, the criteria had to be used specifically for MNM. The toxicological properties of MNM were to be taken into account and inhalation was regarded as the most likely exposure route.
We defined MNM according to the definition adopted by the European Commission from 2011 which defines a nanomaterial "a natural, incidental or manufactured material containing particles in an unbound state or as an aggregate and where for 50% or more of the particles in the number size distribution, one or more external dimensions is in the size range 1-100 nm. In specific cases and where warranted by concerns for the environment, health, safety or competitiveness the number size distribution threshold of 50% may be replaced by a threshold between 1 and 50%. By derogation from the above, fullerenes, graphene flakes and single wall carbon nanotubes with one or more external dimensions below 1 nm should be considered as nanomaterials." MNM hold specific properties due to their small particle size, however, research has shown that this may not always be the case for toxicological properties since other characteristics than particle size may be drivers of toxicity. Specific properties due to other characteristics rather than the small size for example chemical composition and other physical characteristics may be associated with adverse health effects (Dusinska et al., 2013; Kroll et al., 2011) .
This literature review includes manufactured nano-objects (nanoparticles, nanofibers, and nanoplates), agglomerates and aggregates form of these materials as well as nanostructured materials. The form of the MNM refers to the physical form of the MNM such as being a powder, liquid, paste or solid form. The terminology for grouping of MNM is adopted from Oomen et al., (2014 Oomen et al., ( , 2015 where the term "group" or "category" represents a number of MNM that share commonalities relevant for risk, identified as one or more common properties in a physical, chemical, exposure, toxicological endpoints, toxicokinetics or fate. A MNM may belong to more than one group or category. This definition of group/category is well in line with the definition published by the OECD in 2014 in a regulatory context (http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/? cote=env/jm/mono(2014)4&doclanguage=en) as well as the definition given by ECHA. As this definition was developed before MNM were considered in regulations, the term grouping also refers to data sharing between MNM and/or non-MNM of the same substance, for example from one specific (nano) form of titanium dioxide to another specific (nano) form of titanium dioxide or ultrafine particles (UFP) to nanoparticles (NP).
Inclusion criteria: We included only review or expert opinion articles which i) describe grouping/categorization strategies for MNM assessing the MNM for specific properties associated with adverse health effects and ii) taking the toxicological properties of MNM into account and inhalation as the most important exposure route.
Exclusion criteria: individual publications describing original in vitro and in vivo toxicity studies were not included.
The literature search strategy and information sources: Based on the concepts of nanomaterials and expert opinion we developed a search profile including search words and terms appropriate for the different databases (Supplementary Material 1). We limited the search by excluding diagnostic procedures, nanomedicine and ecotoxicology. We searched Medline through PubMed, Embase, OSH Update from 2000 to 2015. Fig. 1 depicts the screening and selection process. The studies were identified using the PICO criteria described above. First, two assessors (SZ and VS) independently screened the abstracts for possible inclusion, according to the inclusion/exclusion criteria. The two assessors discussed any differences in the assessment and if no agreement was reached, the paper was included for further assessment. The N.E. Landvik et al. Regulatory Toxicology and Pharmacology 95 (2018) 270-279 Entities classified in regard to their similarities will be tested once with a standardized testing strategy.
15. Arts et al., 2014 Arts et al., , 2015 Arts et al., , 2016 Consortium/industry/ USA and Europe N.E. Landvik et al. Regulatory Toxicology and Pharmacology 95 (2018) 270-279 selected papers were then read in full to check their eligibility following the inclusion criteria. Finally, a third reviewer (NEL) evaluated the included articles. Data extraction and synthesis: From the included proposals, we extracted data on research group and country of origin, proposed groups, proposed criteria for grouping and arguments or theory for the criteria or grouping proposals.
Results
The search resulted in 805 records originally identified after excluding duplicates, 695 were excluded based on the exclusion criteria after the titles were screened. 148 articles including thirty-eight papers from additional searches were selected according to the inclusion criteria, and added to the 110 remaining records, resulting in a total of 148 articles. All the 148 publications were screened by reading the abstract and followed by exclusion of 126 studies as they did not meet one or more of our inclusion criteria. This resulted in 22 papers that fulfilled our inclusion criteria. Several groups of authors published more than one paper on their proposal leading to 17 proposals as listed in Table 1 and described below.
Description of the included proposals
Of the 17 proposals there were 5 that proposed concrete groups, where one was with environmental focus (Olson and Gurian, 2012) and four of the proposals focussed specifically on human health concerns (Table 1) . Of the 17 proposals, 14 proposed criteria for grouping, 9 of these only proposed criteria's for assessing of MNM but no further groupings. Some authors used several articles with the same or similar proposals for grouping or criteria for grouping of MNM, these where counted as the same proposal. The proposals originated from American or European countries and were put forward by individual researchers, international or national research groups, industry-related groups, consortiums and governmental agencies.
Description of the criteria and opinions on grouping per proposal
In 2007, Warheit et al. (2007) summarized the highlights of a workshop arranged by "The European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC)". The main topic of the workshop was to discuss how to develop testing strategies for the safety of nanomaterials. The workshop looked into current and future challenges with the focus on the characterization of nanomaterials, exposure routes and the assessment of hazard. This article did not include the use of modelling tools for MNM risk assessment; it rather dealt with how to standardize in vitro and in vivo testing of nanomaterials to gain insight into their mode of action. For characterization of nanomaterials, it was highlighted that the working definition of nanoparticles was < 100 nm in one dimension or < 1000 nm to include aggregates and agglomerates. To assess the toxicity of nanomaterials the determination of nanoparticle composition, dissolution, surface area and characteristics, size, size distribution and shape were suggested to be the most important properties. With regard to a general testing approach for human health hazard evaluation of MNM, a stepwise approach was recommended. This included in vitro screening as the first step, assessing the reactivity of the nanomaterials, followed by different levels of in vivo testing. The in vivo testing included a tier 1 testing for short-term exposure effects in rats or mice exposed by inhalation (or intratracheal instillation). Evaluating lung inflammation and cytotoxicity, cell proliferation, and histopathology of the respiratory tract and the major extrapulmonary organs as endpoints. In addition to the tier 1 testing, it should be performed tier 2 testing to evaluate long-term exposure effects. The same endpoints as studied in the tier 1 test should be evaluated. In addition determination of particle deposition, translocation and disposition was suggested to be included and additional studies designed to study sensitive populations may also be relevant.
Hansen et al. (Hansen, 2013; Hansen et al., 2008b) are of the opinion to categorize MNM based on the location of the nanoscale structures. According to this approach MNM may be grouped into three main categories and further subcategorized into different subgroups: 1) Materials that are nanostructured in the bulk, meaning that the materials are nanostructured in three dimensions. 2) Materials that contain nanostructures on their surfaces. 3) Materials containing nanostructured particles defined as free nanosized structures in at least two dimensions with various forms and shapes (i.e quantum dots, fullerenes, nanotubes and nanowires). The authors emphasize that the physicochemical and biological properties of various MNM differ substantially as do the potential risks they may pose. They argue that nanomaterials must be categorized based on the location of the nanoscale structure in the system/material before their hazards can be assessed. They propose that the categorization framework to be applied to the suggested hazard identification approach aimed at identifying causality between inherent physicochemical properties and observed adverse effects reported in the literature. They have then tested the workability of the proposed procedure where a database was generated noting the reported inherent physicochemical properties of the nanoparticles tested and the main effects observed. In general, there was a lack of sufficient characterization of the studied materials and it was not possible to find a link between the effects and the specific properties of the materials. Hansen and colleagues therefore recommend that there should be a strong focus on the material characterization in future. It should be noted that the review by Hansen and colleagues was written almost 10 years ago (in 2008). In such, it is one of the earliest attempts to investigate possibilities for categorization of MNM and since then, as described earlier in this report, most of the reviewed publications emphasize on the importance of material characterization to understand human health effects of MNM but also the effects the organisms in the environment. Kuempel et al. (2012) , describes the concepts and challenges of using reference nanomaterials (benchmark MNM) for hazard-and riskbased categorization of MNM. Kuempel et al., point out the need for development of health-based criteria for evaluation of exposure controls at work place due to existence of a large number of substances including nanomaterials currently with no occupational exposure limits. Particularly, there is limited health hazard data to evaluate the needs for exposure control at workplace, despite of being produced and used by workers. The authors argue that control of exposures at the workplace is the most important measure to prevent health effects (for example lung diseases) related to exposure by inhalation to MNM. They further discuss the need for development of a science-based hazard and risk categorization of MNM for decision-making for control of occupational exposures at the work environment. They propose that a possible strategy would be to select benchmark materials (reference MNM) based on their modes of action, evaluate the hazard and develop risk estimates, and then apply a systematic comparison of new MNM with the benchmark materials in the group with the same mode of action. Based on the mode of action, following examples are given to illustrate quantitative risk assessment methods for possible benchmark particles and occupational exposure control groups: high solubility particles (i.e ZnO leading to release of toxic ions and acute lung/systemic effects), poorly soluble low toxicity particles (i.e TiO 2 , Carbon black, toxicity related to size and amount deposited leading to lung inflammation, fibrosis and cancer), poorly soluble high toxicity particles (crystalline silica and nickel oxide, toxicity related to deposited amount and surface reactivity i.g generation of ROS) and fibrous particles (i.g CNTs and CNFs, toxicity related to biodurability/biopersistency, aspect ratio, migration to mesothelium leading to lung inflammation, fibrosis, cancer and mesothelioma). The authors suggest development of occupational exposure limits for representative reference particles for each of the above mentioned mode of action categories. The benchmark particles can then be linked to specific exposure control bands to achieve assessment of health hazard and quantitative risk for the purpose of development of effective exposure control practices in the work environment. The authors acknowledge that obtaining sufficient dose-response data, based on standard testing, to systematically evaluate the MNM physicochemical properties influencing their biological activity (mode of action), will be a challenge. In the absence of substance-specific information, categorization processes will involve science-based analyses and default assumptions.
Olson (Olson and Gurian, 2012) argues on the importance of taking into account the large number of commercialised available products containing MNM and the subsequent increased relevance to understand their effect on human health and the ecosystem in risk assessment. Persistent and toxic MNM have the largest potential for damaging the environment and the authors suggest a classification system that groups MNM in regard to these characteristics. Since persistency is more easily assessed compared to toxicity, they propose to first screen for persistent compounds. MNM that are categorized as persistent should be studied for possible toxic effects and need a higher burden of proof of their nontoxicity before they enter the commercial market. The authors further state that compounds that are non-persistent, but toxic may damage the local environment, but have less impact globally. They suggest that a lower burden of proof may be acceptable for nanomaterials that are less persistent.
Nel et al., , describe alternative testing strategies (ATS) in two different papers. One of the published works summarizes stakeholders' opinions from a workshop discussing the use of ATS for NM safety assessment. It was a general consensus to use ATS, such as High Throughput Screening (HTS), High Content Screening (HCS), and predictive toxicological approaches, as tools for risk assessment purposes. Such approaches can help prioritize the potential hazardous NM or selected NM categorized in groups that needs further testing. The use of ATS may help in reducing the number of in vivo tests in risk assessment, but not replace them. It was also highlighted the need for stakeholders to be engaged in development of framework that includes ATS.
In the second publication Nel et al., , elaborate on a predictive toxicological testing strategy for toxicity of MNM, since physicochemical properties alone may not always predict the toxicity of the MNM. This testing strategy is based on the idea that MNM inducing similar biological pathways, endpoints or outcomes may be grouped or categorized into defined libraries of MNM using the omics (i.e transcriptomic, proteomic, metabolomic, etc) approaches. The authors argue on the use of mechanism-based high throughput (HTS) in vitro screening assays to predict physicochemical characteristics that may cause pathological or disease outcomes in vivo. The results from the in vivo studies are then used to validate the HTS in vitro results and to establish QSAR to be used for ranking of hazard by combining in vitro and in vivo testing approaches. This approach is, as argued by the authors, a more efficient toxicity testing approach due to use of quantitative, mechanistic and pathway-based toxicity testing in human cells using HTS approaches instead of qualitative and descriptive animal testing. The authors describe four key elements or ingredients necessary for the predictive toxicological approach: i) for having a well-characterized nanoparticle library, they have synthesized a small library of metal oxides (TiO 2 , CeO 2 , ZnO) in which physicochemical properties were rigorously characterized before screening for cytotoxicity, ROS or pro-inflammatory toxicological endpoints. The assays showed a high level of toxicity and ROS generation for ZnO in mammalian cells. Based on these results, and oxidative stress as a main toxicity mechanism, a HTS was developed to track oxidative stress responses for metal oxide nanomaterials. Similar strategies were used to develop a predictive toxicological testing system for profibrogenic effects of multiwalled carbon nanotubes and toxicity of silica and silver nanomaterials. ii) The second requirement for a predictive toxicological approach is development of the appropriate HTS methods that are predictive of adverse outcomes in vivo. The use of mechanistic cellular injury responses that can be related to the pathological responses in vivo is the best platform that exists; iii) One of the best HTS examples regarding the mechanistic injury pathways is screening for ROS and oxidative stress responses to the bandgap of metal and metal oxide nanomaterials, surface defects and release of toxic ions, iv) development of in silico tools for data analysis, data transformation and modelling of HTS data. An example of application of the approach proposed by Nel et al., is the original publication by Wang et al. (2015) that discusses the above predictive toxicological approach based on the pro-fibrogenic effects for tiered testing of carbon-based MNM. They argue that the dispersal state and surface reactivity of carbon based MNM play important roles in triggering a pro-fibrogenic adverse outcome pathway, which could prove helpful for hazard ranking and a proposed tiered testing approach for large categories of carbon based nanomaterials. Gebel et al. (2014) , have performed a critical review of the available research and proposed a guide for grouping of nanomaterials for the purpose of hazard assessment. The scope of their review was limited to hazard assessment of MNM that may be of concern for the health of workers and the consumers. The authors proposed grouping the toxicological effects of MNM in three categories based on the exposure route and mode of action. In summary, they found that the adverse health effects from MNM were mostly linked to toxicity caused by 1) the MNM chemical properties, 2) fibrous MNM and 3) granular biodurable nanoparticles (GBP). More specifically, the toxicity of MNM in category 1) is mediated by the chemical properties of its components, such as released ions or functional groups on the surface. Some examples of these are cadmium-based quantum dots (release of Cd ions), nanosilver (release of Ag ions) and zinc oxide (release of Zn ions). Furthermore, this category of MNM may also contain reactive functional groups on their surfaces that also cause toxicity. Nano crystalline silica is an example where generation of free radicals by functional groups are likely to be relevant for its toxicity. The catalytic properties if present on the surface of the MNM, may also lead to toxic effects. For example, hydrogenation, C-C coupling reactions, CO oxidation and alcohol oxidation may be relevant for toxicity of gold nanoparticles. The chemical composition of MNM is important for chemically mediated toxicity where the chemicals may be packed in or bound to a nanomaterial and as a consequence the chemical constituents may be released from the particles to produce toxicity. The authors suggest that MNM in the category 1) should be evaluated on a case-by-case basis. Category 2) comprises rigid biopersistent respirable fibrous MNM with high aspect ratio (known as WHO fibres). These high aspect ratio nanomaterials (HARNs) may act through an asbestos-like mode of action. Some multi-walled carbon nanotubes (MWCNT) such as Mitsui-7 have been classified as group 2B carcinogens by WHO's International Agency for Research on cancer (IARC) (Grosse et al., 2014) . Shorter (non-WHO fibers) and non-rigid nanofibers may fall under the category of 'granular biodurable particles'. The authors propose using the experience with so-called WHO fibers (such as asbestos) regarding human health effects of the fibrous MNM. Category 3) of MNM includes respirable granular biodurable particles also known as poorly soluble particles (PSPs), or poorly soluble, low toxicity particles (PSLPs). These MNM may after inhalation, cause chronic pulmonary inflammation, fibrosis, secondary mutagenicity and eventually lung cancer. However, Gebel et al., argue that exposure by the inhalation route is important for the possible negative health effects of these MNM. Other routes of exposure to GBPs such as intravenous, oral or skin, apparently do not show effects at the nanoscale. Examples of GBP at the nanoscale are high volume production MNM such as carbon black and titanium dioxide dusts, according to the author. Rats exposed to nanosized carbon black and nanosized titanium dioxide have shown chronic inflammation and malignant tumors in the lung and these effects were considered to be relevant for extrapolation to humans. The authors then argue that the literature data available on health effects of granular biodurable nanoparticles can be used for hazard assessment of the category of GBP MNM.
The article by Lynch et al. (2014) is an opinion article intended to N.E. Landvik et al. Regulatory Toxicology and Pharmacology 95 (2018) 270-279 stimulate discussion and ideas on different approaches for grouping of MNM based on their potential toxic effects and modes of action. Cellular toxicological endpoints of MNM may be many including inflammation, cell death, DNA damage, changes in metabolome, transcriptome, proteome with various modes of action. Lynch and colleagues describe a principle components analysis (PCA) approach for predicting MNM toxicity, where the experimentally determined physicochemical parameters are mapped onto three axes or three principle components described as intrinsic properties (i.e. those attributed to the nanostructure that are independent of the interactions with external environment), extrinsic properties (i.e. those affected by the interaction with the external environment) and composition. In the PCA approach, toxicity of MNM is predicted when a specific nanomaterial sits in terms of each of those three scales mentioned above. According to the authors in the principle component analysis model, for each toxicity endpoint the principle components such as physicochemical characteristics, biological interactions etc., that contribute to each toxic endpoint could be identified, allowing comparisons to be made across toxicological endpoints and establishment of quantitative (nano) activity relationships. The authors then argue that the PCA grouping approach will potentially provide simple and robust classification framework for toxicological classification of MNM to support the nanosafety legislation. Stone et al. (2014) , described development of an alternative testing strategy. The authors developed a framework for the research priorities for effective development of an intelligent testing strategy (ITS) to allow risk evaluation of MNM. The ITS presented by the authors uses the same risk assessment approach as for other chemicals, and puts emphasis on a thorough physicochemical characterization of MNM, taking into account where necessary, nano relevant properties such as size, shape and surface characteristics. ITS is described as a process that allows the risks of MNM to be assessed accurately (making the correct conclusion), effectively (availability of the appropriate tools to achieve the risk assessment) and efficiently (short assessment time and low cost). The need to test MNM on a case-by-case basis is thereby reduced, a task which is time-and resource demanding and almost impossible to accomplish. For each of the major elements of risk assessment i.e physicochemical characterization, exposure identification, hazard identification and modelling, key-priority research areas are described via a series of hexagon diagrams structured into a time perspective of short-term (< 5 years), mid-term (5-10 years), long-term (10-15 years) and distant (> 15 years). The prioritization hexagon diagrams provide a tool which individual stakeholders can adapt to meet their own particular needs and to deliver an ITS for MNM risk assessment. The authors believe that such an approach would over time, reduce the need for testing by increasing the reliability and sophistication of in silico approaches. Bos et al. (2015) , present a risk assessment strategy in the context of the MARINA (managing risk of nanoparticles) project. The proposed strategy is exposure-driven and focuses on defining relevant and realistic exposure scenarios. Integration of the parameters exposure, fate/ kinetics and hazard throughout the whole process, especially during data gathering and for the risk characterization is an important aspect of this strategy. Determination of physicochemical properties of MNM and their importance for exposure, fate/kinetics and hazard is integrated in the strategy. The MARINA risk assessment strategy comprises of two phases: phase 1 (problem framing) consists of a data evaluation step and a step where relevant exposure scenarios (RES) are identified. Phase 2 (risk assessment) consists of the steps risk characterization including risk management options; defining data needs; data gathering and data evaluation. The authors argue that the MARINA strategy and its principles, and the underlying components are in accordance with the recommendations and requirements outlined by the ITS-NANO and that the framework of the MARINA strategy can be practically implemented in accordance with the ITS-NANO recommendations. Godwin et al. (2015) , describe ATS, as was also reviewed by Nel et al. Godwin and colleagues define ATS as new and emerging tools and approaches involving in vitro and in silico test systems that could be used as alternatives or supplementations to in vivo testing strategies (particularly testing in mammals) to generate nanosafety data to be used for hazard and risk assessment and/or modelling purposes. By using carbon nanotubes as illustrative examples of nanomaterials, they discuss how data from alternative testing strategies can be used to facilitate MNM categorization according to risk potential and how such an approach could facilitate regulatory decision-making in the future. The example of CNTs is used because of the challenge with grouping of these materials and the increasing production and use of the CNTs in the world marked, however, many of the principles discussed in the ATS approach are broadly applicable to other MNM. When discussing the example of CNTs in an ATS perspective the authors propose a tiered approach where data obtained from both in vitro assays as well as linked, predictive short term (90 days) in vivo data is suggested to be used for categorization. As such, the mechanistic and predictive toxicological assays assign the MNM that are expected to have similar toxicological profiles among the materials in the same group. The proposed ATS approach starts with acquiring information on potential for inhalation exposure to the MNM (hence human health concern), toxicity, and then tier one testing (risk suggested based on ATS assays i.e profibrogenicity through AOP assay), tier 2 testing (short term in vivo testing by bolus administration) and tier 3 testing (short term i.e 90 day in vivo inhalation testing).
Krug (2014) discusses literature published since 2000 on uptake of nanomaterials in vivo in the lung, gastrointestinal tract and skin, and compares the use of instillation and inhalation as exposure methods to evaluate effects in the lung. He further discusses weaknesses in the literature published in the field of nanotoxicology, raises concern on the quality of the results published and their lack of harmonization. Of his recommendations are working towards harmonized or international standards in experimental procedures. Grouping is not in the objective of the review by Krug, but his concerns are of relevance when the lack of comparability and consistency in nanotoxicology research makes risk assessment challenging and question the foundation in grouping approaches.
Landsiedel (2016) discusses integrated approaches for the testing and assessment of MNM that could ensure the safety of MNM, while reducing costs and expenditure for testing and also complying with the 3Rs approach (replacing, reducing, and refining) to reduce animal testing. The author reasons that the complexity of MNM requires developing diverse and comprehensive grouping approaches as compared to classical grouping and read-across strategies correlating a substance's structural characteristics with its biological activity (mode of action). On the other hand, exposure to MNM occurs to a diverse number of particles including primary particles, aggregates, and agglomerates of a range of sizes and different surface coatings that further may change over the lifecycle of the MNM. Physicochemical properties of MNM affect biokinetics and hazard potential, and this may complicate the correlation between a certain material property and a biological effect. So far, no single physicochemical property of MNM completely correlates with their observed biological endpoints. Therefore, grouping of MNM should not be restricted to the determination of nanostructureactivity relationships, but it should also consider the substance's entire source-to-adverse-outcome pathway. Adverse outcome pathways link the interactions of substances with biological target tissues resulting in cellular responses (adverse outcomes). The author then suggests a multi-perspective grouping approach according to (1) production, use and release of MNM over the entire lifecycle of the MNM; (2) the physicochemical properties of MNM, which can differ in different lifecycle phases; (3) the uptake, biodistribution and biopersistence of MNM in an organism in accordance with various physicochemical properties of the MNM in different tissues; (4) the early and apical biological effects of MNM. According to the author, a single MNM can be assigned to N.E. Landvik et al. Regulatory Toxicology and Pharmacology 95 (2018) 270-279 a variety of different groups or, possibly, no group at all. The author then concludes that grouping of MNM by exposure, use and release should be applied to determine MNM of concern and also complemented by data on biopersistence and biokinetics. Grouping of MNM by their biophysical interactions and early biological effects should form an intrinsic part of all subsequent tiers of the integrated approaches for the testing and assessment of MNM with the aim of refining concerns until risk assessment can be performed. In this way in vivo studies for apical toxic effects would be kept to a minimum and restricted to benchmark MNM, serving as reference for a group or those MNM which could not be assigned to a group. This approach to MNM risk assessment serves to ensure product safety of a large number of MNM in different modifications, uses and lifecycle stages, and reducing the need for animal testing (complying with the 3R) and reducing the testing costs as well. Oomen et al., (2014 Oomen et al., ( , 2015 , discuss five key elements to be taken into account for grouping/categorization and read-across of MNM 1) Including grouping and read across as approaches in MNM regulatory framework or strategy. They also suggest that the grouping approaches should be applicable for the current as well as future MNM. 2) A solid scientific justification to support proposals for grouping and read-across of MNM. Such documentation is already required under REACH and recommended in the OECD 2014 guidance for grouping (OECD, 2014) .
3) The MNM considered should be clearly identified and characterized. This will elucidate the existing information on the MNM as well as a foundation for further risk assessment applications such as grouping and read across. Others (Hansen et al., 2008a (Hansen et al., , 2014 have also highlighted a strong focus on characterization of MNM, suggesting to split the physicochemical properties into four classes such as chemical identity, physical identity, fundamental behaviour and reactivity. 4) The full life cycle of the MNM should be taken into account. Through the production, the MNM may show different properties and their toxic potential may change during their life cycle. It is therefore important to consider these possible changes for grouping and read-across of MNM. 5) The mechanistic toxicological pathways should be considered. This element may streamline and simplify grouping and read-across for a target MNM.
Walser et al., (Walser and Studer, 2015) , suggest grouping of MNM in different "clouds" dependent on the MNM chemical composition, size distribution and shape. The "clouds" would further be classified into different entities dependent on their similarities. For hazard assessment, the entities with similar toxic profiles would be tested once through a standardized test strategy, moving away from current caseby-case assessments. However, to be able to use this approach the need to prioritize research that increase the knowledge on the MNM and their mode of action and adverse outcome pathway was highlighted. The authors further argue the need to develop clear rules for grouping and hazard evaluation for the industry. Arts et al., (2014 Arts et al., ( , 2015 Arts et al., ( , 2016 , highlight lack of specific regulatory guidance for grouping of nanomaterials. The authors discuss published approaches for MNM grouping and put emphasis on the importance of addressing all life cycle aspects of the MNM. They propose that intrinsic material properties, system-dependent properties, exposure, uptake, biokinetics, and apical biological effects (toxicological endpoints) are relevant for grouping and should be taken into consideration. They further argue that none of the existing grouping concepts fully take into account all of these aspects, and that all these aspects should be combined into the available concepts leading to a comprehensive 'multiperspective' framework for the grouping of MNM that will also address all of the aspects of MNM life cycles. The authors delineate a decisionmaking framework for the grouping and testing of nanomaterials (DF4nanoGrouping). The DF4nanoGrouping suggests grouping MNM by characterizing the MNM in a tiered approach and the three suggested tiers are based on the 1) material properties 2) system-dependent properties and 3) in vivo solubility/biopersistence. Depending on the MNM properties in regard to the tiered criteria, the MNM may be assigned to four main groups including subgroups within each group. Main group 1 (soluble MNM) comprises of non-biopersistent MNM where the chemical composition is more important for risk assessment than the native nanostructure (as produced). For MNM in this group no further nanospecific subgrouping or nanospecific hazard assessment will be performed, rather read-across of the properties of the dissolved materials to the corresponding bulk materials will be performed. Main group 2 MNM (biopersistent HARNs) are those rigid MNM fulfilling the WHO fibers criteria and also the biopersistency criteria, and the toxicity is dependent on morphology and long half-life. The HARNs may further be divided in subgroups depending on their degree of solubility in water or biopersistency. The main group 3 (passive nanomaterials) includes biopersistent but non-fibrous MNM such as granular biodurable particles that do not have reactive surfaces, do not cause acute cellular effects and do not exist in a well dispersed form. However, high concentrations may be accumulated in body organs and regardless of their "passive state" they may lead to negative effects because of their particulate nature. MNM embedded in the matrices of products are also included in this main group 3. This group of MNM is considered to have low or no hazard potential. The main group 4 (active MNM) consists of non-fibrous biopersistent MNM whose hazardous potential is based upon their chemical composition, dissolution rate, dispersibility, surface reactivity, or cellular effects. These MNM are expected to have adverse toxicological effects at lower doses, and MNM may be ranked into subgroups based on in vivo results. Further subgrouping may be performed based upon dustiness (degree of mobility in air), dispersibility in physiological fluids, and the uptake, biopersistency, and effects in vitro and in vivo. Braakhuis et al. (2016) , focus on the induction of biological responses by MNM with a particular focus on induction of inflammation when the exposure route is through inhalation. This is particularly of interest when occupational exposure and workers health is considered since both induction of inflammation and immunosuppression are of major concern. Braakhuis et al., discuss different ways of grouping MNM for the purpose of risk assessment with emphasis on inhalation exposure and pulmonary inflammation as an important toxicological endpoint. The authors state that there is evidence to suggest that the total surface area of the MNM may be important for their inflammatory responses. They argue that since the relation between single intrinsic particle characteristics and the severity of pulmonary inflammation is unknown, grouping of MNM by their intrinsic characteristics alone is not sufficient to predict their inflammatory responses in the lung after inhalation. Furthermore, biokinetics of MNM should be taken into account as the dose present at a given target site over time would be dependent on the biokinetics. Characteristics of MNM may change during the process of their lifecycle, resulting in human exposure to different forms and doses of the MNM. The parameters important for the kinetic behaviour of MNM are not the same as the parameters that determine the hazard. There is often lack of essential information on the biokinetics and in situ characteristics of MNM, it is therefore important to make efforts to include these informations in the testing strategies. Braakhuis and colleagues argue that grouping of MNM will be valuable for risk assessors when information on intrinsic characteristics, lifecycle, biokinetics and effects are all combined. Dekkers et al. (2016) , propose a risk assessment strategy where approaches for grouping, read-across and quantitative structure activity relationships (QSARs) are integrated in prioritization of the MNM applications that may lead to high human health risks. Furthermore, the nanospecific properties of the MNM that may influence the exposure, kinetics and hazard assessment aspects of the MNM are discussed. The authors summarise six elements, each of which may play an important role in the proposed risk assessment strategy: 1) exposure potential where measurement of exposures is important for performing risk assessment in addition to assessment of the hazard. In this element are also included routes of exposure or the amount of the MNM used, both of which are important for identification of the exposure hotspots during the entire lifecycle of the MNM that are being assessed. 2) Dissolution capacity of a nanomaterial is important since this element is associated with the stability of a nanomaterial. The dissolution element can have a great impact on the exposure potential, behaviour and effects on absorption and distribution of the MNM into the body. If a nanomaterial is immediately disintegrated into its ionic or molecular forms before reaching its target the effects may not be nanospecific anymore and therefore it is suggested to perform a traditional nonnanospecific risk assessment. If, the MNM under assessment is not rapidly dissolved and remains stable, a risk assessment of the nanomaterial behaviour and effects should be evaluated. 3) Nanomaterial transformation may occur during the entire lifecycle of a MNM. A MNM may undergo a number of transformations during manufacturing and subsequent modifications may occur (coatings, abrasion, oxidation, reduction, agglomeration, aggregation) in interaction with body biomolecules (protein/lipid corona). All these transformations may affect the health related behaviour (dissolution, absorption, distribution) of the MNM. 4) Accumulation of MNM in the body is an important element in a risk assessment perspective even though the sole accumulation may not be harmful and it has been shown that some biodurable MNM may accumulate in some target organs without toxicological effects. 5) Genotoxicity of MNM is a major concern since it is a main mechanism in carcinogenic effects of MNM and there is some data showing that some MNM are genotoxic in cell culture studies and carcinogenic in animal studies. 6) As for non-nanomaterials, immunotoxicity of MNM is of concern since some of the MNM might lead to alterations in immune responses which may further cause human health effects such as allergic responses, chronic inflammation, fibrosis, etc. Dekkers and colleagues then give a detailed description of the above mentioned six elements that are addressed in the approach they have proposed where the two main objectives of the approach are to i) prioritize the most hazardous applications of MNM, ii) identify the most important information needed to deal with nanospecific issues related to risk assessment. These objectives are addressed in three phases where objective one (prioritization of applications) is dealt with in phase one and objective number two (identification of information) is addressed in phase two and three. The objective of phase one is to screen and prioritize MNM based on: identification of the MNM with the most hazardous potential (category 1), MNM for which a non-nanospecific risk assessment can be performed (category 2) and MNM that need further evaluations (category 3). The objective of the phase two and beyond is to gather the most needed information (specific applications, exposure scenarios, lifecycle stage, etc) to deal with nanospecific issues for risk assessment. These phases will identify possibilities of grouping and read across based on physicochemical characteristics and experimental in vitro results. The three most important phases of the proposed approach are fully described by the authors. They believe that the phase one in the proposed approach is useful for regulatory purposes (policy makers, regulators, the industry) to prioritize the applications of MNM that need to be addressed most urgently depending on the hazardous potential of the MNM on human health. The phase two and beyond will also benefit the regulators and the industry to identify the needs for information on nanospecific issues and possibilities for grouping and read across. It is argued that the proposed approach may enable identification of those situations where the use of nanospecific grouping, read-across and QSAR tools are likely to become feasible in the future, and to point towards the generation of the type of data that is needed for scientific justification, which may lead to regulatory acceptance of nanospecific applications of these tools.
Summary of the proposed groups and arguments
There was both communality and diversion of opinions on how to group MNMs and we have provided an overview of what is available in a systematic way without evaluating what is correct or incorrect. Four of the five proposals for groups suggested one or more of the following five groups: fibrous versus non-fibrous or granular particles, biopersistent versus non-biopersistent materials, materials with high solubility versus low solubility, chemically reactive versus chemically non-reactive materials, materials with high toxicity versus low toxicity. One proposal suggested to group MNMs based on one, two or three dimensions on the nanoscale.
Five out of the 13 proposals indicated that their proposal was based on a viable test strategy, three suggested that this was based on mode of action, three based it on a prediction model resulting from physicochemical properties, and one each based on results of in vitro and animal research, similarity with the process for bulk material, exposure scenarios, or potential for induction of inflammation.
Discussion
The continuous increase in production of new MNM highlights the need for efficient and reliable risk assessment strategies. A case-by-case testing is time consuming and may delay regulation of particular MNM of health concern. Grouping MNM for risk assessment purposes may streamline the process, but underlines the need for reliable grouping strategies detecting the MNM of risk. Of the four proposals that suggest a concrete grouping the main elements that are in common among three of them are MNM that are chemically active or soluble, MNM that have a fibrous structure and MNM that are biopersistent. There is some variation in the combination of these elements between proposals. Considering further need for adverse effect testing of the MNM it would be particularly the MNM with fibrous structure and MNM that are biopersistent that may require additional testing. Furthermore, there was one older proposal that consists of grouping based on the number of nano-dimensions but this has not been taken over by other research groups.
Across all proposals that describe criteria, there is consensus that physical and chemical properties of the MNM are the key elements to be considered for grouping of MNM. Physical-chemical characterization of the test MNM has been emphasized in multiple studies and minimum criteria for characterization have been suggested by several groups and leading scientists (Oberdorster et al., 2005; Powers et al., 2006; Sayes and Warheit, 2009; Warheit, 2008; Xia et al., 2010) . The need for thorough material characterization has been asked for by regulatory agencies in the USA (i.e EPA, FDA, NIOSH) and in Europe (i.e OECD, ECHA). This is to avoid erroneous grouping of MNM into hazard categories, acknowledging that no single physicochemical property of MNM completely correlates with their observed biological endpoints. Characterization is critical to try and understand any correlates and, for regulatory agencies to use a case-by-case approach to assess the hazard of each MNM.
The important criteria for grouping of MNM are 1) physical (size/ shape/morphology), chemical properties (composition/form/chemistry such as metals, metal oxides, carbon-based, polymeric etc.); 2) functionality, 3) modes of action, similar biodurability/biokinetics linked to toxicological response(s), 4) interaction with the endogenous protein and lipid components in the body leading to formation of protein/lipid corona. Genotoxicity, was not regarded as a specific mechanism that is inherent to the nano-size of the MNM and only once used as a grouping criterion. However, there are some data showing genotoxicity of MNM in cell culture studies and carcinogenic in animal studies and it may be good reasons to consider nanoforms of carcinogenic and mutagenic bulk materials as a specific criteria for grouping.
Another line of thinking for grouping was based on ranking MNM according to priority for testing with the main criterion the amounts or volumes of commercial values (production and consumption volumes). Similarly, some research groups proposed to rank MNM based on transformation or different exposure scenarios along the life cycle of the nanomaterial. This may affect the occupational health of MNM workers involved in various aspects of exposures to the same MNM from the beginning of research and development in research labs, moving to production procedures, formulation, processing, use and otherwise handling of MNM, including recycling and disposal.
Following a systematic approach, we could identify areas of consensus and differences of opinions on criteria for grouping MNM to facilitate risk assessment. The strength of our review is that we used a systematic approach to locate and analyse proposals and the systematic approach allowed for comparison of the various proposals. We also noted both the communality and diversion of opinions on how to group MNMs and we have not attempted to create evaluation criteria to judge one as being more correct than the other. We have rather, provided an overview of what is available in a systematic way without evaluating what is correct or incorrect.
This review is limited based on the method of search, since recommendations of classifications in primary research articles or in review articles (not included in title or abstract) would be missed. However, the identification and review of 17 articles specific for classification most likely represents the breadth of recommendations by scientists and workshops. Additionally, this is a classification scheme to prioritize limited resources to the most likely hazardous MNM, and as such, this review does not include the internal deliberations of regulatory agencies on the risk/hazard-benefit of individual medicines or commercial products to the consumers.
Another limitation of our analysis is that we considered all proposals as equally valid because we did not have criteria to assess the quality of the proposals. Our conclusions are based on the similarities between proposals of various research groups. We did not consider findings that may support major concern for workers health following MNM exposures by the dermal or ingestion/oral routes, compared to occupational inhalation exposure of MNM. We would like to note that regarding surface modifications/functionalization of MNM, we are aware that nontoxic MNM may become biologically active by modifying the surface chemistry, however, we have not pursued these aspects in this report, this is however an important aspect when characterizing the MMN.
The opinions of various research groups concur in listing a variety of MNM characteristics that may be used or explored further for assessing risks from groups of nanomaterials. There are also modifying factors which may interfere with results from testing of groups. Overall, researchers suggest that for MNM to be harmful there are three different mechanisms 1) specific toxicity of the material, 2) inhalation and biodurability in the lungs and 3) a specific mode of action of high aspect ratio nanofibers, not different from WHO fibers.
Future research should evaluate if grouping of nanomaterials in the proposed groups indeed leads to similar toxicological characteristics and what are the characteristics of MNM that best predict this shared toxicological profile.
